Regeneron Pharmaceuticals said that the monoclonal antibodies of its REGEN-COV cocktail are active against all known variants of concern of Covid-19, including Omicron and Delta.

According to the US biotech company, REGEN-COV, which comprises the casirivimab and imdevimab antibodies, has diminished potency against Omicron, but is active against the Delta variant, which is more prevailing in the US.

Regeneron Pharmaceuticals said that it is confirming that multiple ‘next generation’ monoclonal antibodies from its collection of fully human monoclonal antibodies targeting SARS-CoV-2 are active against the Omicron (B.1.1.529) and Delta (B.1.617.2) variants, in addition to the other variants of concern.

The biotech company said that subject to regulatory discussions, it expects the Covid-19 drug to enter the clinic in Q1 2022.

REGEN-COV is yet to be approved by the US Food and Drug Administration (FDA). However, it has emergency use authorization for the treatment and post-exposure prophylaxis in some high risk individuals.

  Casirivimab, Coronavirus, COVID-19, Delta, Imdevimab, Omicron, REGEN-COV, Regeneron Pharmaceuticals, USA